|Day Low/High||11.45 / 13.64|
|52 Wk Low/High||2.85 / 10.69|
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
The best move here is to stay focused on stock picking but manage positions tightly.
Shares of the Botox competitor could correct/consolidate after a recent surge.